Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
General Outlook
In simple terms, Horizon Therapeutics Public Limited Company has 228.995 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.752% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.141%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.120%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.047% return, is a testament to Horizon Therapeutics Public Limited Company's adeptness in optimizing resource deployment. Horizon Therapeutics Public Limited Company's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.085%. Furthermore, the proficiency of Horizon Therapeutics Public Limited Company in capital utilization is underscored by a remarkable 0.061% return on capital employed.
Stock Prices
Horizon Therapeutics Public Limited Company's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $115.7, while its low point bottomed out at $115.19. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Horizon Therapeutics Public Limited Company's stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”